Uncontrolled phase I dose escalation, safety and pharmacokinetic study of SSR244738 administered as a one-hour intravenous infusion weekly in patients with refractory solid tumors
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2007
At a glance
- Drugs SSR 244738 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 22 Feb 2007 New trial record.